If you liked this article you might like

Why EpiPen, Why Now? Analysts Explain the Timing of Mylan's Trouble
Pfizer Confirms $14 Billion Takeover of Cancer Drugmaker Medivation
Gilead May Be Better Off Splitting Itself in Two, Analysts Say
Should Gilead Split in Two?